UY28260A1 - PHARMACEUTICAL COMBINATION - Google Patents

PHARMACEUTICAL COMBINATION

Info

Publication number
UY28260A1
UY28260A1 UY28260A UY28260A UY28260A1 UY 28260 A1 UY28260 A1 UY 28260A1 UY 28260 A UY28260 A UY 28260A UY 28260 A UY28260 A UY 28260A UY 28260 A1 UY28260 A1 UY 28260A1
Authority
UY
Uruguay
Prior art keywords
combination
pharmaceutical combination
eletriptan
prevention
treatment
Prior art date
Application number
UY28260A
Other languages
Spanish (es)
Inventor
Michael John Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY28260A1 publication Critical patent/UY28260A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El presente invento proporciona una combinación de (a) eletriptan, o una de sus sales farmacéuticamente aceptable, y (b) bicarbonato de sodio. La combinación proporciona una absorción rápida de eletriptan cuando se toma por vía oral. La combinación es útil para el tratamiento o la prevención de una enfermedad para la que es indicado un agente agonista de 5-HT1, particularmente en el tratamiento de una migrana o para la prevención de una recurrencia de migrana.The present invention provides a combination of (a) eletriptan, or a pharmaceutically acceptable salt thereof, and (b) sodium bicarbonate. The combination provides rapid absorption of eletriptan when taken orally. The combination is useful for the treatment or prevention of a disease for which a 5-HT1 agonist agent is indicated, particularly in the treatment of a migraine or for the prevention of a migraine recurrence.

UY28260A 2003-04-11 2004-04-06 PHARMACEUTICAL COMBINATION UY28260A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
UY28260A1 true UY28260A1 (en) 2004-11-30

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28260A UY28260A1 (en) 2003-04-11 2004-04-06 PHARMACEUTICAL COMBINATION

Country Status (12)

Country Link
EP (1) EP1615635A1 (en)
JP (1) JP2006522790A (en)
AR (1) AR044009A1 (en)
BR (1) BRPI0409127A (en)
CA (1) CA2521902A1 (en)
MX (1) MXPA05010070A (en)
NL (1) NL1025908C2 (en)
PA (1) PA8599901A1 (en)
PE (1) PE20050086A1 (en)
TW (1) TW200423929A (en)
UY (1) UY28260A1 (en)
WO (1) WO2004089365A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
IT1393700B1 (en) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint SYNTHESIS OF 3 - {[(2R) -1-METHYLPYROLIDIN-2-IL] METHYL} -5- [2- (PHENILSULFONYL) ETYL] -1H-INDOL
JP6878021B2 (en) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 Pharmaceutical composition containing triptan and ascorbic acid
JP7237375B2 (en) 2018-07-03 2023-03-13 アクスサム セラピューティクス インコーポレイテッド Pharmaceutical composition containing meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (en) * 1986-08-01 1988-11-25 Zambon Spa PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (en) * 1993-03-26 1997-06-11 Zambon Spa PHARMECEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20040162333A1 (en) * 2003-02-19 2004-08-19 Naima Mezaache Rapid absorption selective 5-HT agonist formulations

Also Published As

Publication number Publication date
BRPI0409127A (en) 2006-03-28
NL1025908A1 (en) 2004-10-13
CA2521902A1 (en) 2004-10-21
NL1025908C2 (en) 2005-11-22
MXPA05010070A (en) 2005-11-23
WO2004089365A1 (en) 2004-10-21
EP1615635A1 (en) 2006-01-18
PE20050086A1 (en) 2005-03-01
TW200423929A (en) 2004-11-16
JP2006522790A (en) 2006-10-05
AR044009A1 (en) 2005-08-24
PA8599901A1 (en) 2005-02-04

Similar Documents

Publication Publication Date Title
BRPI0408396A (en) orally consumable, rapidly dissolving films containing pharmaceutically active agents
ES2545205T3 (en) Combination of azelastine and ciclesonide
NO20045434L (en) A combination of an NMDA antagonist and acetylcholinesterase inhibitors for the treatment of Alzheimer's disease
BR0215184A (en) orally active taxane derivative pharmaceutical compositions having increased bioavailability
CY1109119T1 (en) PHARMACEUTICAL FORMS OF LONG-TERM RELEASE INCLUDING LAMOTRIGIN
ECSP099501A (en) FORMULATIONS OF UNIT DOSE AND METHODS FOR THE TREATMENT OF THROMBOSIS WITH AN ORAL INHIBITOR OF FACTOR XA
UY28285A1 (en) CONSUMABLE FILES BY ORAL ROUTE THAT DISSOLVES QUICKLY, CONTAINING A SWEETENER
AR041089A1 (en) PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
ECSP003652A (en) TREATMENT OF COMBINATION WITH I1-1ra AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1
AR054253A1 (en) ASSOCIATION BETWEEN RAILWAY AND AN ARTEMISININE DERIVATIVE FOR THE TREATMENT OF PALUDISM
CY1110130T1 (en) MORPHOLINE PRODUCTS FOR USE AS DOPAMINE AGONISTS IN THERAPEUTIC DISEASE Therapeutic Treatment I.A.
UY28260A1 (en) PHARMACEUTICAL COMBINATION
MA27262A1 (en) MICROCAPSULES FOR DELAYED AND CONTROLLED RELEASE OF PERINDOPRIL
BR9912588A (en) Preventing migraine recurrence
AR038305A1 (en) ORGANALLY DISPERSABLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL
PA8552301A1 (en) METHOD FOR THE TREATMENT OF PRIMARY INSOMNIA
DOP2004000871A (en) PHARMACEUTICAL COMBINATION
AR039162A1 (en) VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION
DK1575362T3 (en) Use of an acaricide powder
AR057403A1 (en) 4- ANILINO-3-QUINOLINCARBONITRILOS FOR THE TREATMENT OF CANCER
CL2004000751A1 (en) PHARMACEUTICAL COMBINATION CONTAINING (A) ELETRIPAN, OR ONE OF ITS SALTS, AND (B) SODIUM BICARBONATE; COMPOSITION AND PHARMACEUTICAL PRODUCT CONTAINING SUCH COMBINATION; AND ITS USE IN THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR TREATMENT AND PREV
UY27741A1 (en) MELOXICAM SUPPOSITORIES
PE20010123A1 (en) 5HT1 RECEPTOR AGONISTS AND A COX-2 INHIBITOR OR AN NSAID FOR THE TREATMENT OF MIGRANA
AR045724A1 (en) ORODISPERSABLE PHARMACEUTICAL COMPOSITION OF AN ANTITROMBOTIC COMPOUND
AR042297A1 (en) ORAL IMMEDIATE RELEASE DOSAGE FORM

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150521